Clinical trials
Unresectable Pancreatic Ductal Adenocarcinoma clinical trials
Below are recruiting unresectable pancreatic ductal adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 67 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07805954RecruitingPhase 3
New targeted pills for first-line metastatic pancreatic cancer
This trial tests two new targeted pills (zoldonrasib and daraxonrasib) compared to the standard chemotherapy (gemcitabine and nab-paclitaxel) as the first treatment for metastatic pancreatic cancer with a specific KRAS G12D mutation. The new pills may specifically attack cancer cells with this mutation.
Phoenix, ArizonaAges 18 years+ - NCT06079346RecruitingPhase 2/Phase 3
New drug with chemotherapy for advanced pancreatic cancer
This trial tests a new drug called OT-101 combined with a standard chemotherapy regimen (mFOLFIRINOX) for people with advanced pancreatic cancer that has spread or cannot be removed. The goal is to see if the combination can help shrink or control the cancer better than chemotherapy alone.
Detroit, MichiganAges 18 years+ - NCT06261359RecruitingPhase 2
CEND-1 plus chemo for first-line pancreatic cancer
This trial tests a new drug called CEND-1 combined with standard chemotherapy for people with advanced pancreatic cancer that has not been treated before. It aims to see if the combination works better than chemo alone.
Beijing, Beijing MunicipalityAges 18–80 - NCT07627711RecruitingPhase 1/Phase 2
CAR-NK cells for advanced pancreatic cancer
This trial tests specially engineered immune cells (CAR-NK cells) designed to find and attack pancreatic cancer cells. The cells target specific proteins on cancer cells and may help people whose cancer has progressed despite prior treatment.
Shenzhen, GuangdongAges 18–75 - NCT07621718RecruitingPhase 3
Zoldonrasib plus chemotherapy for metastatic pancreatic cancer with KRAS mutation
This trial tests whether adding a new drug called zoldonrasib to standard chemotherapy works better than chemotherapy alone for pancreatic cancer that has spread and has a specific KRAS G12D mutation. The goal is to see if this combination helps patients live longer and control their cancer better.
Phoenix, ArizonaAges 18 years+ - NCT07619521RecruitingPhase 1/Phase 2
Combination drug therapy for advanced pancreatic cancer
This trial tests two targeted drugs, selumetinib and DS-8201a (trastuzumab deruxtecan), for advanced pancreatic cancer that has spread or cannot be removed. The combination may help people whose tumors have specific markers (KRAS mutation and HER2 positivity).
New Haven, ConnecticutAges 18 years+ - NCT07619313RecruitingPhase 1
AB801 with Chemotherapy and Immunotherapy for Bile Duct or Pancreatic Cancer
This study tests a new drug called AB801 combined with standard chemotherapy and immunotherapy for advanced bile duct cancer (cholangiocarcinoma) or pancreatic cancer. The goal is to see if this combination can shrink tumors and help patients live longer.
Los Angeles, CaliforniaAges 18 years+ - NCT07595172RecruitingPhase 1/Phase 2
New drug combination for advanced pancreatic cancer
This study tests whether combining three treatments—NALIRIFOX (chemotherapy), Adebrelimab (an immune-boosting antibody), and PULSAR (radiation)—can help people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if this combination works better than standard care.
Chengdu, SichuanAges 18–75 - NCT05218889RecruitingPhase 1/Phase 2
Surufatinib plus immunotherapy for advanced pancreatic cancer
This trial studies whether a combination of surufatinib and immunotherapy (camrelizumab, plus an “AS” medicine) can slow or shrink advanced pancreatic cancer that has spread. It is for people starting treatment for advanced disease for the first time and may help those who have measurable tumors and meet safety test limits.
BeijingAges 18–75 - NCT07490301RecruitingPhase 2/Phase 3
Study of a new drug combo for first-line metastatic pancreatic cancer
This trial tests a new targeted drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) for people with advanced pancreatic cancer that has spread. The goal is to see if this combination works better than current treatments.
New Haven, ConnecticutAges 18 years+ - NCT07480928RecruitingPhase 1/Phase 2
CAR-NK cell therapy for advanced pancreatic cancer
This trial tests a new type of immune cell therapy called CAR-NK cells that target two proteins (MSLN and MUC1) often found on pancreatic cancer cells. It is for people whose cancer has spread or cannot be removed, and who have already tried at least one standard treatment.
Shenzhen, GuangdongAges 18–75 - NCT07483983RecruitingPhase 2
Study of ASP3082 for advanced lung and pancreatic cancers with KRAS G12D mutation
This trial tests a new drug, ASP3082, for people with advanced non-small cell lung cancer or pancreatic cancer that has a specific gene change called KRAS G12D. The study will collect tumor and blood samples to understand how the cancer responds or becomes resistant to the treatment.
Villejuif, FranceAges 18 years+ - NCT07454642RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug called AVA6103 for people with certain advanced solid tumors that have not responded to standard treatments. The drug may help by targeting a protein on cancer cells and interfering with their ability to multiply.
Scottsdale, ArizonaAges 18 years+ - NCT07328607Recruiting
Comparing Keyhole vs Open Pancreas Surgery
This trial compares two surgical approaches for removing tumors in the head of the pancreas or nearby areas: 'keyhole' (laparoscopic) surgery versus traditional open surgery. The goal is to see if the keyhole method offers similar results with a faster recovery.
Minya, Minya GovernorateAges 18–75 - NCT07255404RecruitingPhase 2
Testing pumitamig with chemotherapy for untreated pancreatic cancer
This trial tests an experimental drug called pumitamig combined with standard chemotherapy for people with advanced pancreatic cancer that has spread and has not been treated yet. The goal is to see if this combination is safe and effective.
Bedford ParkAges 18 years+ - NCT07241676Enrolling by invitation
Pancreatic cancer surgery and early recurrence study
This study looks at patients who had surgery to remove pancreatic cancer to understand what factors might lead to the cancer coming back early. If you have had surgery for pancreatic cancer and are interested in helping researchers learn more, this may be a fit.
Padova, PDAges 18 years+ - NCT07199764RecruitingPhase 2
Maintenance therapy using combination immunotherapy for pancreatic cancer
This trial tests a combination of immunotherapy drugs (targeting CD40 and other immune cells) as a maintenance treatment for people with advanced pancreatic cancer that has not grown or has shrunk after initial chemotherapy. The goal is to see if this approach can keep the cancer from progressing longer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07155525Recruiting
Glue to prevent leaks after pancreas surgery
This trial tests whether a special medical glue (Glubran® 2) applied to the pancreas during surgery can help prevent fluid leaks. It is for people undergoing a Whipple procedure for pancreatic cancer who have a soft pancreas.
Minya, Minya GovernorateAges 18–75 - NCT07157033RecruitingPhase 1/Phase 2
Testing XER-001 with radiation for advanced pancreatic cancer
This trial tests a new way to deliver a drug called amifostine (XER-001) alongside intense radiation therapy (SBRT) for people with locally advanced pancreatic cancer that can't be surgically removed. The goal is to see if it's safe and effective at protecting healthy tissue while targeting the tumor.
Duarte, CaliforniaAges 18 years+ - NCT07155850Recruiting
Testing YntraDose before chemotherapy for advanced pancreas cancer
This trial tests a new treatment called YntraDose, given directly into the pancreas tumor before standard chemotherapy. It is for people with locally advanced pancreatic cancer that cannot be removed by surgery.
RomaAges 18 years+ - NCT07148830Recruiting
Surgery technique study for pancreatic cancer patients
This trial tests a specific surgical method called mesopancreatic excision during Whipple surgery for pancreatic cancer. It may help remove more cancer tissue and improve outcomes for patients with resectable disease.
Minya, Minya GovernorateAges 18–75 - NCT07101679RecruitingPhase 2
Study of radiation, chemo, and immunotherapy for advanced pancreatic cancer
This trial tests a combination of chemotherapy (GnP), an immunotherapy drug (serplulimab), and targeted radiation (SBRT) as a first treatment for locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this triple therapy can shrink the tumor and improve outcomes.
Chengdu, SichuanAges 18–75 - NCT07033689RecruitingEarly Phase 1
Testing Suizenji for newly diagnosed pancreatic cancer
This trial tests a new ultrasound treatment called Suizenji for people with pancreatic cancer that cannot be removed by surgery. The goal is to see if it can safely target the tumor.
San Francisco, CaliforniaAges 18 years+ - NCT06998940RecruitingPhase 3
Chemotherapy with or without panitumumab for pancreatic cancer
This trial tests whether adding a targeted drug called panitumumab to standard chemotherapy can help people with a certain type of pancreatic cancer that has spread. It is for patients whose tumors do not have a KRAS mutation and who have already had one line of chemotherapy.
Anchorage, AlaskaAges 18 years+
Hear when a new Unresectable Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for unresectable pancreatic ductal adenocarcinoma?
- Yes. Clin2 currently lists 67 recruiting unresectable pancreatic ductal adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a unresectable pancreatic ductal adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a unresectable pancreatic ductal adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Borderline Resectable Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (mPDAC)
- Resectable Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.